This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Teva Pharmaceuticals USA, Inc.
Reference
James E, et al. Budgetary Impact of Bendamustine Ready-to-Dilute Products in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma to a United States Infusion Facility. ClinicoEconomics and Outcomes Research : 22 Mar 2021. Available from: URL: https://doi.org/10.2147/CEOR.S297284
Rights and permissions
About this article
Cite this article
Short-duration bendamustine ready-to-dilute product in CLL/NHL: clinical and economic advantages. PharmacoEcon Outcomes News 875, 29 (2021). https://doi.org/10.1007/s40274-021-7608-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7608-0